Hikma successfully completes $500 million 5-year Eurobond issue

London, July 9, 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company rated BBB- / stable (S&P) and Ba1 / stable (Moody’s), announces that it has successfully completed a $500 million 5-year Eurobond, which will carry an annual coupon of 3.25%.

Press Release Corporate 9 July 2020

Khalid Nabilsi, Hikma CFO said, “We are very pleased to announce the successful placement of this Eurobond despite the COVID-19 pandemic which has caused uncertainty in the financial markets. The bond was three times oversubscribed backed by high interest from investors globally – a clear indication of the continuing confidence of international investors in our financial prospects. The net proceeds of the issue will strengthen the company’s financial position and provide the financial flexibility to capitalize on opportunities to support our strategic growth plans.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.